Rohm, Theresa V. http://orcid.org/0000-0001-8498-1018
Castellani Gomes Dos Reis, Felipe http://orcid.org/0000-0001-8357-5261
Isaac, Roi
Murphy, Cairo
Cunha e Rocha, Karina
Bandyopadhyay, Gautam
Gao, Hong
Libster, Avraham M.
Zapata, Rizaldy C.
Lee, Yun Sok http://orcid.org/0000-0001-7967-4734
Ying, Wei http://orcid.org/0000-0002-4890-7256
Miciano, Charlene http://orcid.org/0000-0001-7653-8876
Wang, Allen http://orcid.org/0000-0001-9870-7888
Olefsky, Jerrold M. http://orcid.org/0000-0003-0392-1705
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (P30DK063491, R01DK101395, DK124298)
Janssen Pharmaceuticals
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_200177)
Larry L. Hillblom Foundation (2023-D-012-FEL, 2023-D-011-FEL)
UC | University of California, Los Angeles (UCLA LIFT-UP)
Foundation for the National Institutes of Health (R00DK115998, R21HD107516, R01DK125560)
Article History
Received: 25 August 2023
Accepted: 6 March 2024
First Online: 11 April 2024
Change Date: 5 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42255-024-01094-9
Competing interests
: W.Y. and J.M.O. are co-investigators on a provisional patent covering the use of miR-690 as an insulin sensitizer. The other authors declare no competing interests.